Rizatriptan Benzoate
Key Dates
Due Date
-
Posted Date
-
Agency & Value
Agency
DLA TROOP SUPPORT
Contract Value
Not provided
Codes & Classification
Solicitation Number
SPE2D2-22-R-0118
NAICS
325412 - Pharmaceutical Preparation Manufacturing
Classification Code
6505
Additional Details
Documents4
The Defense Logistics Agency (DLA) Troop Support has issued Solicitation SPE2D2-22-R-0118, seeking to establish a national requirements contract for the supply of Rizatriptan Benzoate tablets. This solicitation supersedes the previously announced presolicitation notice SPE2D2-22-R-0009, which was replaced due to a systems issue. The procurement is designed to ensure a reliable, long-term supply of Rizatriptan Benzoate, a pharmaceutical product used in the treatment of migraines, for various federal agencies.
The scope of this procurement encompasses multiple dosage forms and packaging configurations of Rizatriptan Benzoate, specifically:
- Disintegrating Tablets, 5 MG, in 3-count and 18-count bottles
- Disintegrating Tablets, 10 MG, in 3-count and 18-count bottles
- Standard Tablets, 5 MG, in 12-count and 18-count bottles
- Standard Tablets, 10 MG, in 12-count and 18-count bottles
The contract will be structured as a firm-fixed price, requirements-type agreement, featuring a one-year base period with four additional one-year option periods. The intent is to establish a national supply source in accordance with FAR 52.216-21 (Requirements), supporting the needs of the Department of Defense, Department of Veterans Affairs, Indian Health Service, and Bureau of Prisons. These agencies will access the contracted products through the DLA and VA prime vendor programs. Annual usage estimates for each line item will be detailed in the Schedule of Supplies section of the solicitation.
This acquisition is classified under NAICS code 325412 (Pharmaceutical Preparation Manufacturing), with a Product Service Code of 6505 (Drugs and Biologicals). The procurement is unrestricted and fully competitive, inviting proposals from all qualified sources. The solicitation will be conducted under FAR Part 12, indicating that the items are considered commercial products.
Interested contractors should note that this opportunity does not include any set-aside requirements; it is open to all capable suppliers. The DLA encourages interested parties to monitor the DLA Bid Board System (DIBBS) and SAM.gov for updates, solicitation documents, and any amendments. Automated notifications can be set up through these platforms to stay informed of any changes.
The primary point of contact for this solicitation is Keith Ryales ([email protected], 215-737-9199), with Jason C. Wray ([email protected], 215-737-0614) serving as the secondary contact. The solicitation was posted on August 25, 2022, with a response deadline of September 9, 2022. The DLA reserves the right to adjust the solicitation release date as necessary.
This opportunity represents a significant, multi-year contract for pharmaceutical manufacturers and distributors with the capability to supply Rizatriptan Benzoate in the specified forms and quantities, and to support the logistical requirements of federal healthcare and correctional agencies nationwide.